|
|
|
Insider
Information: |
Nohra Guy P |
Relationship: |
Director |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
19 |
|
Direct
Shares |
10,292,949 |
|
Indirect Shares
|
31,541,253 |
|
|
Direct
Value |
$216,706,954 |
|
|
Indirect Value
|
$224,987,676 |
|
|
Total
Shares |
41,834,202 |
|
|
Total
Value |
$441,694,631 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
2
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
31.9%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
AVADEL Pharmaceuticals Plc |
AVDL |
N/A |
2003-10-02 |
0 |
2003-10-02 |
6,443 |
Premium* |
|
Rigel Pharmaceuticals Inc |
RIGL |
N/A |
2004-08-20 |
9,593 |
2004-08-20 |
29,715 |
Premium* |
|
Renovis Inc |
RNVS |
Director |
2004-02-10 |
0 |
2004-02-10 |
42,240 |
Premium* |
|
Crucell Nv |
CRXLY |
N/A |
2004-05-25 |
6,436 |
2004-05-25 |
0 |
Premium* |
|
Icagen Inc |
ICGN |
10% Owner |
2005-02-08 |
0 |
2005-02-08 |
2,135,003 |
Premium* |
|
Cutera Inc |
CUTR |
Director |
2005-08-15 |
0 |
2005-08-15 |
0 |
Premium* |
|
Neurogesx Inc |
NGSX |
10% Owner |
2007-05-07 |
0 |
2007-05-07 |
1,735,673 |
Premium* |
|
Acelrx Pharmaceuticals Inc |
ACRX |
Director |
2011-02-16 |
0 |
2013-09-20 |
2,507,974 |
Premium* |
|
Ellie Mae Inc |
ELLI |
10% Owner |
2011-04-20 |
1,528,363 |
2011-04-20 |
1,524,804 |
Premium* |
|
Esperion Therapeutics, Inc. |
ESPR |
10% Owner |
2013-07-01 |
0 |
2014-10-21 |
2,552,189 |
Premium* |
|
Aerie Pharmaceuticals Inc |
AERI |
10% Owner |
2014-05-22 |
3,616,099 |
2013-10-30 |
0 |
Premium* |
|
Trevena Inc |
TRVN |
10% Owner |
2014-02-05 |
0 |
2014-12-10 |
4,390,262 |
Premium* |
|
Zs Pharma, Inc. |
ZSPH |
Director |
2015-12-17 |
0 |
2014-06-23 |
3,230,090 |
Premium* |
|
Evofem Biosciences Inc |
EVFM |
Former 10% Owner |
2015-12-30 |
1,339,776 |
2014-11-25 |
2,595,257 |
Premium* |
|
Kalvista Pharmaceuticals Inc |
KALV |
Director |
2015-04-14 |
0 |
2015-04-14 |
4,343,550 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
10% Owner |
2015-05-12 |
1,778,064 |
2015-05-12 |
0 |
Premium* |
|
Allakos Inc. |
ALLK |
10% Owner |
2021-03-04 |
0 |
2021-03-04 |
6,448,053 |
Premium* |
|
Sutro Biopharma Inc |
STRO |
10% Owner |
2018-10-01 |
1,944,901 |
2018-10-01 |
0 |
Premium* |
|
Bioventus Inc. |
BVS |
Director |
2023-08-16 |
69,717 |
2023-08-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
86 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
AVDL |
AVADEL Pharmaceuticals Pl... |
See Footnotes |
|
2003-10-02 |
4 |
D |
$33.25 |
$63,175,000 |
I/I |
(1,900,000) |
6,443 |
|
- |
|
RNVS |
Renovis Inc |
Director |
|
2004-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
2,166,112 |
42,240 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-02-19 |
4 |
S |
$20.00 |
$2,233,920 |
I/I |
(111,696) |
13,003 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-02-19 |
4/A |
S |
$20.00 |
$1,489,280 |
I/I |
(74,464) |
13,835 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-03-24 |
4 |
S |
$20.00 |
$149,740 |
I/I |
(7,487) |
13,668 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-05 |
4 |
S |
$22.95 |
$27,540 |
I/I |
(1,200) |
13,641 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-06 |
4 |
S |
$21.00 |
$203,700 |
I/I |
(9,700) |
13,424 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-07 |
4 |
S |
$21.00 |
$1,266,342 |
I/I |
(60,300) |
12,077 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-21 |
4 |
S |
$21.27 |
$146,747 |
I/I |
(6,900) |
11,923 |
|
- |
|
CRXLY |
Crucell Nv |
See Footnote |
|
2004-04-21 |
4 |
A |
$0.00 |
$0 |
I/I |
1,668,451 |
45,854 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-22 |
4 |
S |
$21.25 |
$40,375 |
I/I |
(1,900) |
11,881 |
|
- |
|
CRXLY |
Crucell Nv |
See Footnote |
|
2004-04-22 |
4 |
S |
$8.21 |
$164,144 |
I/I |
(20,000) |
45,304 |
|
- |
|
CRXLY |
Crucell Nv |
See Footnote |
|
2004-04-23 |
4 |
S |
$8.11 |
$5,045 |
I/I |
(622) |
45,287 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-23 |
4 |
S |
$21.32 |
$279,285 |
I/I |
(13,100) |
11,588 |
|
- |
|
CRXLY |
Crucell Nv |
See Footnote |
|
2004-04-26 |
4 |
S |
$8.15 |
$90,323 |
I/I |
(11,078) |
44,983 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-26 |
4 |
S |
$21.26 |
$36,142 |
I/I |
(1,700) |
11,550 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-27 |
4 |
S |
$21.26 |
$153,038 |
I/I |
(7,200) |
11,389 |
|
- |
|
CRXLY |
Crucell Nv |
See Footnote |
|
2004-04-27 |
4 |
S |
$8.44 |
$265,803 |
I/I |
(31,500) |
44,117 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-28 |
4 |
S |
$21.25 |
$170,000 |
I/I |
(8,000) |
11,210 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-29 |
4 |
S |
$21.25 |
$739,514 |
I/I |
(34,800) |
10,433 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-04-30 |
4 |
S |
$21.25 |
$178,500 |
I/I |
(8,400) |
10,245 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-05-03 |
4 |
S |
$21.31 |
$2,028,398 |
I/I |
(95,200) |
8,119 |
|
- |
|
CRXLY |
Crucell Nv |
See Footnote |
|
2004-05-06 |
4 |
S |
$7.80 |
$1,560,000 |
I/I |
(200,000) |
38,620 |
|
- |
|
RIGL |
Rigel Pharmaceuticals Inc |
See footnotes |
|
2004-05-07 |
4 |
S |
$21.50 |
$66,650 |
I/I |
(3,100) |
8,050 |
|
- |
|
CRXLY |
Crucell Nv |
See Footnote |
|
2004-05-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,405,251) |
0 |
|
- |
|
86 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|